Shanghai Pharmaceutical Co., Ltd Secures Multiple Partnerships at CIIE
At the 7th China International Import Expo (CIIE), China-based Shanghai Pharmaceutical Co., Ltd (SPH, SHA:...
NYSE: NVS
Novartis Forges Partnerships at CIIE to Strengthen Radioligand Therapy Ecosystem in China
At the 7th China International Import Expo (CIIE), Swiss pharmaceutical giant Novartis (NYSE: NVS) announced...
Novartis’ Trispecific Antibody PIT565 Secures NMPA Approval for Clinical Trial
Swiss pharmaceutical giant Novartis (NYSE: NVS) has received acceptance for its clinical trial application for...
Novartis Secures FDA Accelerated Approval for Scemblix in Newly Diagnosed CML Patients
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that its drug Scemblix (asciminib) has received accelerated...
Monte Rosa Therapeutics Strikes Licensing Deal with Novartis for VAV1 Degraders
US-based Monte Rosa Therapeutics (NASDAQ: GLUE) has entered into a licensing agreement with Swiss pharmaceutical...
Novartis’s Kisqali Receives Positive CHMP Opinion for Early Breast Cancer Treatment in the EU
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has announced that the Committee for Medicinal Products...
Chengdu Baiyu Pharmaceutical Strikes Licensing Deal with Novartis for Unannounced Anti-Tumor Asset
Chengdu Baiyu Pharmaceutical Co., Ltd., a Chinese pharmaceutical company, has entered into a licensing agreement...
Novartis’s Brolucizumab Accepted for Review by China’s CDE for Potential DME Treatment
The Center for Drug Evaluation (CDE) has indicated that Novartis (NYSE: NVS), the Swiss pharmaceutical...
Novartis’ Cemiplimab Approved in China for Moderate-to-Severe Atopic Dermatitis
Novartis (SWX: NOVN, NYSE: NVS)’s Chinese arm has announced that it has received approval from...
Voyager Therapeutics Secures Licensing Deal with Novartis for Gene Therapy Capsid
Voyager Therapeutics Inc. (NASDAQ: VYGR), a U.S.-based biotechnology company, has announced a licensing agreement with...
Novartis Builds Two Radioligand Therapy Facilities in U.S. to Expand Cancer Treatment Capabilities
Novartis AG (NYSE: NVS), a Swiss pharmaceutical giant listed on the NYSE under the ticker...
Novartis and Versant Ventures Launch Borealis Biosciences with a Focus on RNA Medicines for Kidney Diseases
Novartis (NYSE: NVS), a Swiss pharmaceutical heavyweight, has joined forces with the US venture capital...
Novartis Intensifies Legal Action Against FDA Over Entresto Generic Approval
Novartis Inc. (NYSE: NVS) is intensifying its efforts to thwart the entry of generic competitors...
Novartis’s Scemblix Receives FDA Priority Review for First-Line CML Treatment
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that the US Food and Drug Administration...
Novartis Partners with Dren Bio to Develop Next-Generation Cancer Therapies
Novartis (NYSE: NVS), a leading Swiss pharmaceutical company, has entered into a strategic collaboration with...
Novartis Delivers Strong Q2 2024 Results with 11% YoY Net Sales Increase
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has released its financial results for the second...
Pharmaceutical Giants Face UK Industry Code Breach Allegations, Including Novartis and Pfizer
Several multinational pharmaceutical corporations have been reprimanded for violating the UK’s Prescription Medicines Code, a...
Novartis Launches Construction of First Radioligand Manufacturing Site in China
Novartis AG (NYSE: NVS), the Swiss pharmaceutical giant, has initiated construction on its second manufacturing...
Novartis’s Scemblix STAMP Inhibitor for CML Accepted for Review by China’s NMPA
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has had its market filing for Scemblix (asciminib)...
Novartis Moves Toward Full Ownership of MorphoSys with Shareholder Squeeze-Out
Novartis AG (NYSE: NVS), the Swiss pharmaceutical giant, is proceeding to fully acquire MorphoSys AG...